Cost effectiveness of cilostazol compared with naftidrofuryl and pentoxifylline in the treatment of intermittent claudication in the UK

References

• Golledge J, Garratt A, Greenhalg RM, et al. Patient-assessed health outcomes in peripheral arterial disease. Eur J Vasc Endovasc Surg 2000;19:109–10
   PubMed Web of Science ®Google Scholar
• Fowkes FG, Housley E, Cawood EH, et al. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991;20: 384–92
   PubMed Web of Science ®Google Scholar
• Bevan EG, Waller PC, Ramsay LE. Pharmacological approaches to the treatment of intermittent claudication. Drugs Aging 1992;2:125–36
   Google Scholar
• Pell JP. Impact of intermittent claudication on quality of life. The Scottish Vascular Audit Group. Eur J Vasc Endovasc Surg 1995;9:469–72
   PubMed Web of Science ®Google Scholar
• Crosby FE, Ventura MR, Frainier MA, et al. Well-being and concerns of patients with peripheral arterial occlusive disease. J Vasc Nurs 1993;11:5–11
   PubMedGoogle Scholar
• Intercontinental Medical Statistics data set specific for UK. Intercontinental Medical Statistics Ltd, Middlesex, UK, 2003
   Google Scholar
• Chapman TM, Goa KL. Cilostazol: a review of its use in intermittent claudication. Am J Cardiovasc Drugs 2003;3:117–38
   PubMedGoogle Scholar
• Thompson PD, Zimet R, Forbes WP, et al. Meta-analysis of results from eight randomised, placebo-controlled trails on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol 2002;90:1314–19
   PubMed Web of Science ®Google Scholar
• Cariski A. Cilostazol: a novel treatment option in intermittent claudication. Int J Clin Prac Suppl 2001;119:11–8
   PubMedGoogle Scholar
• Lehert P, Comte S, Gamand S, et al. Naftidrofuryl in intermittent claudication: a retrospective analysis. Cardiovasc Pharmacol 1994;23(Suppl 3):S48–52
   PubMedGoogle Scholar
• Cameron HA, Waller PC, Ramsay LE. Drug treatment of intermittent claudication: a critical analysis of the methods and findings of published clinical trials, 1965–1985. Br J Clin Pharmacol 1988;26: 569–76
   Google Scholar
• Green RM, McNamara J. The effects of pentoxifylline on patients with intermittent claudication. J Vasc Surg 1988;7:356–62
   PubMed Web of Science ®Google Scholar
• AbuRahma AF, Woodruff BA. Effects and limitations of pentoxifylline therapy in various stages of peripheral vascular disease of the lower extremity. Am J Surg 1990;160:266–70
   PubMed Web of Science ®Google Scholar
• Beebe HG, Dawson DL, Cutler BS, et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med 1999;159:2041–50
   PubMed Web of Science ®Google Scholar
• Strandness DE, Dalman RL, Panian S, et al. Effect of cilostazol in patients with intermittent claudication: a randomised, double-blind, placebo-controlled study. Vasc Endovasc Surg 2002; 36:83–91
   PubMedGoogle Scholar
• Adhoute G, Andreassian B, Boccalon H, et al. Treatment of stage II chronic arterial disease of the lower limbs with the serotonergic antagonist naftidrofuryl: results after 6 months of a controlled, multicenter study. J Cardiovasc Pharmacol 1990;16(Suppl 3): S75–80
   PubMedGoogle Scholar
• Kieffer E, Bahnini A, Mouren X, et al. A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication. Findings of the Naftidrofuryl Clinical Ischemia Study (NCIS). Int Angiol 2001;20:58–65
   PubMed Web of Science ®Google Scholar
• Moody AP, al-Khaffaf HS, Lehert P, et al. An evaluation of patients with severe intermittent claudication and the effect of treatment with naftidrofuryl. J Cardiovasc Pharmacol 1994;23(Suppl 3):S44–7
   Google Scholar
• Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000;109:523–30
   PubMed Web of Science ®Google Scholar
• Porter JM, Cutler BS, Lee BY, et al. Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J 1982;104:66–72
   PubMed Web of Science ®Google Scholar
• Lindgarde F, Jelnes R, Bjorkman H, et al. Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Scandinavian Study Group. Circulation 1989;80:1549–56
   PubMed Web of Science ®Google Scholar
• NHS 2003 Reference Costs. Department of Health, London, 2004
   Google Scholar
• Monthly Index of Medical Specialites 2003 editions. London: Haymarket Publications Ltd
   Google Scholar
• Netten A, Curtis L. Unit costs of health and social care 2003. University of Kent, Canterbury. Personal Social Services Research Unit 2003
   Google Scholar
• Drug Tariff 2003. Available from http://www.drugtariff.com
   Google Scholar
• Hiatt WR. Medical treatment of peripheral arterial disease and claudication. NEJM 2001;344:1608–19
   PubMed Web of Science ®Google Scholar
• Hiatt WR. New treatment options in intermittent claudication: the US experience. Int J Clin Prac Suppl 2001;119:20–8
   PubMedGoogle Scholar
• Radack K, Wyderski RJ. Conservative management of intermittent claudication. Annals Int Med 1990;113:135–46
   PubMed Web of Science ®Google Scholar
• Gillings DB. Pentoxifylline and intermittent claudication: review of clinical trials and cost-effectiveness analyses. Cardiovasc Pharmacol 1995;25(Suppl 2):S44–50
   PubMedGoogle Scholar
• De Vries SO, Visser K, de Vries JA, et al. Intermittent claudication: cost effectiveness of revascularization versus exercise therapy. Radiology 2002;222:25–36
   PubMed Web of Science ®Google Scholar
• Savage P, Ricci MA, Lynn M, et al. Effects of home versus supervised exercise for patients with intermittent claudication. Cardiopulm Rehabil 2001;21:152–7
   Google Scholar
• Troeng T, Bergqvist D, Janzon L, et al. The choice of strategy in the treatment of intermittent claudication – a decision tree approach. Eur J Vasc Surg 1993;7:438–43
   PubMedGoogle Scholar
• Hunink MG, Wong JB, Donaldson MC, et al. Revascularization for femoropopliteal disease. A decision and cost-effectiveness analysis. JAMA 1995;274:165–71
   Google Scholar
• Weinstein MC, Fineberg HV. Clinical decision analysis. Philadelphia: WB Saunders Co., 1980; p.228–65
   Google Scholar
• Boccalon H, Lehert P, Mosnier M. Effect of naftidrofuryl on physiological walking distance in patients with intermittent claudication. Ann Cardiol Angeiol (Paris) 2001;50:175–82
   PubMedGoogle Scholar
• Money SR, Herd JA, Isaacsohn JL, et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. Vasc Surg 1998;27:267–74; discussion 274–5
   Google Scholar